ArticleDiagnostics (Basel, Switzerland)2022
Gastrointestinal Involvement in Dermatomyositis.
Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinical features, triggers, and risk factors of severe gastrointestinal involvement in anti-NXP2-positive juvenile dermatomyositis: a retrospective cohort study.Pediatric rheumatology online journal · 2026Article
- Early detection and intervention in dermatomyositis: current evidence and clinical implications.Clinical rheumatology · 2026Review
- A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data.Clinical rheumatology · 2025Observational
- Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study.Rheumatology and therapy · 2025Article
- Emergencies in inflammatory rheumatic diseases.Rheumatology international · 2024Review
- Gastrointestinal Vasculitis in Adult Patient With Dermatomyositis Presenting as Hematemesis.ACG case reports journal · 2024Article
- Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody.RMD open · 2024Article
- Juvenile dermatomyositis complications: navigating gastrointestinal perforations and treatment challenges, a case report.Frontiers in pediatrics · 2024Article
- Dermatomyositis: Practical Guidance and Unmet Needs.ImmunoTargets and therapy · 2024Review
- Anti-nuclear matrix protein 2 antibody-associated juvenile dermatomyositis with gastrointestinal perforations was successfully treated with traditional therapeutic drugs combined with vedolizumab: a case report after a long-term follow-up and a review of the literature.Frontiers in pediatrics · 2024Article
- Pneumatosis cystoides intestinalis in dermatomyositis: a case series report and literature review.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis is a systemic vasculopathy mainly affecting skin, muscle and lung, but may affect the gastrointestinal tract. We aim to describe clinical characteristics of patients with severe gastrointestinal involvement related to dermatomyositis in our center and medical literature. We retrospectively analysed these patients in our center, including cases of erosions/ulcers, perforation or digestive bleeding. Reported cases from April 1990 to April 2021 were reviewed through PubMed and Cochrane. From our cohort (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.